Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-23T20:31:37.350Z Has data issue: false hasContentIssue false
  • English
  • Français

CSF Myelin Basic Protein Levels in Acute Optic Neuritis and Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

K.G. Warren ,
Ingrid Catz  and
T.A. McPherson
K.G. Warren*
Affiliation:
The Multiple Sclerosis Research Clinic, Department of Medicine (Neurology), University of Alberta and Cross Cancer Institute, Edmonton
Ingrid Catz
Affiliation:
The Multiple Sclerosis Research Clinic, Department of Medicine (Neurology), University of Alberta and Cross Cancer Institute, Edmonton
T.A. McPherson
Affiliation:
The Multiple Sclerosis Research Clinic, Department of Medicine (Neurology), University of Alberta and Cross Cancer Institute, Edmonton
*
9-101A Clinical Sciences Building, 83rd Avenue at 112 Street, Edmonton, Alberta, Canada T6G 2G3.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Normal CSF-MBP levels as determined by a RIA were <6.2 ng/ml CSF (mean 3.9). Eighty percent of patients with acute optic neuritis have CSF-MBP levels greater than 6.2 ng/ml (mean 7.6 ng/ml CSF). Five of 7 patients with acute internuclear ophthalmoplegia due to an initial exacerbation of demyelination have CSF-MBP levels above 6.2 ng/ml (mean 6.8 ng/ml). Fifty percent of MS patients with chronic progressive disease have CSF-MBP levels above 6.2 ng/ml (mean 6.7 ng/ml). MS patients experiencing monosymptomatic exacerbations show elevated CSF-MBP levels in 75% of cases (mean 8.2 ng/ml). MS patients experiencing polysymptomatic exacerbations show significantly higher levels of CSF-MBP (mean 22.3 ng/ml) than the patients with monosymptomatic exacerbations. Ninety-five percent of MS patients experiencing polysymptomatic exacerbations have elevated levels of CSF-MBP.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 10 , Issue 4 , November 1983 , pp. 235 - 238
Copyright
Copyright © Canadian Neurological Sciences Federation 1983

References

Cohen, S.R., Brooks, B.R., Herndon, R.M. and McKhann, CM. (1980). A diagnostic index of active demyelination: Myelin basic protein in cerebrospinal fluid. Annals Neurol. 8(1) 25–31.Google ScholarPubMed
Cohen, S.R., Herndon, R.M. and McKhann, G.M. (1976). Radioimmunoassay of myelin basic protein in spinal fluid. New Engl. J. Med. 295(26) 1455–1457.CrossRefGoogle ScholarPubMed
Diebler, G.E., Marteuson, R.E. and Kies, M.W. (1972). Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prepr. Biochem 2: 139–165.Google Scholar
Herndon, R.M. and Johnson, M. (1970). A method for the electron microscopic study of cerebrospinal fluid sediment. J. Neuropathol Exp. Neurol. 29: 320–330.Google ScholarPubMed
Hsuing, H.M., Wu, J. and McPherson, T.A. (1978). Silica gel radioimmunoassay for myelin basic protein. Clin. Biochem., 11 (2): 54–56.CrossRefGoogle Scholar
Hunter, W.M. and Greenwood, F.C. (1962). Preparation of 131I labelled human growth hormone of high specific gravity. Nature 195: 495.CrossRefGoogle Scholar
Link, H. and Muller, R. (1971). Immunoglobulins in Multiple Sclerosis and Infections of the nervous system. Arch. Neurol. 25: 326–344.CrossRefGoogle ScholarPubMed
McPherson, T. A., Gilpin, A. and Seland, T. P. (1972). Radioimmunoassay of cerebrospinal fluid for encephalitogenic basic protein: A diagnostic test for MSπ Can. Med. Assn. J. 101, 856–859.Google Scholar
Palfreyman, J.W., Thomas, G.T. and Ratcliffe, J.G. (1978). Radioimmunoassay of human myelin basic protein in tissue extract, cerebrospinal fluid and serum and its clinical application to patients with head injury. Clin. Chim. Acta. 82: 259.CrossRefGoogle ScholarPubMed
Warren, K.G., Gordon, P.A. and McPherson, T.A. (1982). Plasma exchange of malignant multiple sclerosis. Can. J. Neurol. Sci. 9(1) 27–30.CrossRefGoogle ScholarPubMed
Whitaker, J.N. (1975). The antigenicity of myelin basic protein: production of antibodies to encephalitogenic protein with DNA — encephalitogenic protein complexes. J. Immunol. 114(2) 823–000.CrossRefGoogle ScholarPubMed
Whitaker, J.N. (1977). Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with Multiple Sclerosis. Neurology 27: 911–920.CrossRefGoogle ScholarPubMed
Whitaker, J.N., et al. (1980). Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Annals Neurol. 7(1).CrossRefGoogle ScholarPubMed